View Clinical Trial (Medical Research Study)

Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy - NCT01086150-12208(Clinical Trial 568030)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Albany
State:  
NY
Zip Code: 12208
Conditions: Diabetic Peripheral Neuropathy
Purpose: The purpose of this study is to see if an investigational drug known as the lidocaine 5% patch is safe and effective in reducing the symptoms of diabetic neuropathy, to examine how topical lidocaine affects the nerve endings, and to determine whether treatment with the lidocaine patch can prevent the potential progression to chronic diabetic neuropathy pain in subjects who did not report pain at the start of the study.
Study summary:
Criteria: Inclusion Criteria: - Group 1: 18-70 years of age, non-diabetic with no nervous system disease (healthy control group) - Group 2: 18-70 years of age with Type I or Type II diabetes with significantly painful diabetic neuropathy (VAS > 40mm at Baseline) - Group 3: 18-70 years of age with Type I or Type II diabetes with non- painful or insignificantly painful diabetic neuropathy (VAS < 40mm at Baseline) Exclusion Criteria: - History of clinically significant liver disease, serious peripheral vascular disease, a blood clotting disorder, or any other medical condition felt to be exclusionary by the investigator - Allergy to lidocaine - Unwillingness to sign informed consent or any other reasons for which the investigator feels the subject cannot complete the study - Women who are pregnant, breastfeeding or trying to become pregnant - History of slow-healing diabetic foot ulcers - Current skin or soft tissue lesions on the foot that will interfere with application of the lidocaine patch and or skin biopsies - Subjects taking Class I antiarrhythmics - HgA1c > 11% - Active cancer within the previous two years except treated basal cell carcinoma of the skin - Co-morbidities that can produce neuropathy - Subjects taking sodium channel blockers within one week of study treatment and throughout the study - Subjects taking any other experimental drugs within 30 days prior to Screening Visit (Visit 1) - Application of lidocaine patch to either foot within two weeks of Screening Visit (Visit 1)
Study is available at: Albany Medical College
Albany, NY 12208
United States

Primary Contact:
Margaret Czerwinski, RN
Email: czerwim@mail.amc.edu
Phone: 518-262-0034

Secondary Contact:
Charles Argoff, MD
Email: argoffc@mail.amc.edu
Phone: 518 262-6538
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.